Metlay, J. P. et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am. J. Respir. Crit. Care Med. 200, e45–e67 (2019).
Pragman, A. A., Berger, J. P. & Williams, B. J. Understanding persistent bacterial lung infections: clinical implications informed by the biology of the microbiota and biofilms. Clin. Pulm. Med. 23, 57–66 (2016).
Mettelman, R. C., Allen, E. K. & Thomas, P. G. Mucosal immune responses to infection and vaccination in the respiratory tract. Immunity 55, 749–780 (2022).
Hewitt, R. J. & Lloyd, C. M. Regulation of immune responses by the airway epithelial cell landscape. Nat. Rev. Immunol. 21, 347–362 (2021).
Cookson, W. O., Cox, M. J. & Moffatt, M. F. New opportunities for managing acute and chronic lung infections. Nat. Rev. Microbiol. 16, 111–120 (2018).
Parmanik, A. et al. Current treatment strategies against multidrug-resistant bacteria: a review. Curr. Microbiol. 79, 388 (2022).
Grief, S. N. & Loza, J. K. Guidelines for the evaluation and treatment of pneumonia. Prim. Care: Clin. Off. Pract. 45, 485–503 (2018).
Kellum, J. A. et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the genetic and inflammatory markers of sepsis (GenIMS) study. Arch. Intern. Med. 167, 1655–1663 (2007).
Kumar, V. Pulmonary innate immune response determines the outcome of inflammation during pneumonia and sepsis-associated acute lung injury. Front. Immunol. 11, 1722 (2020).
Mookherjee, N., Anderson, M. A., Haagsman, H. P. & Davidson, D. J. Antimicrobial host defence peptides: functions and clinical potential. Nat. Rev. Drug Discov. 19, 311–332 (2020).
Dijksteel, G. S., Ulrich, M. M., Middelkoop, E. & Boekema, B. K. Lessons learned from clinical trials using antimicrobial peptides (AMPs). Front. Microbiol. 12, 616979 (2021).
Izadpanah, A. & Gallo, R. L. Antimicrobial peptides. J. Am. Acad. Dermatol. 52, 381–390 (2005).
Zhang, L.-j. & Gallo, R. L. Antimicrobial peptides. Curr. Biol. 26, R14–R19 (2016).
Di, Y. P., Kuhn, J. M. & Mangoni, M. L. Lung antimicrobial proteins and peptides: from host defense to therapeutic strategies. Physiol. Rev. 104, 1643–1677 (2024).
Mahlapuu, M., Björn, C. & Ekblom, J. Antimicrobial peptides as therapeutic agents: opportunities and challenges. Crit. Rev. Biotechnol. 40, 978–992 (2020).
Hou, X. et al. Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis. Nat. Nanotechnol. 15, 41–46 (2020).
Steinstraesser, L. et al. Skin electroporation of a plasmid encoding hCAP-18/LL-37 host defense peptide promotes wound healing. Mol. Ther. 22, 734–742 (2014).
Pyzik, M., Kozicky, L. K., Gandhi, A. K. & Blumberg, R. S. The therapeutic age of the neonatal Fc receptor. Nat. Rev. Immunol. 23, 415–432 (2023).
Czajkowsky, D. M., Hu, J., Shao, Z. & Pleass, R. J. Fc-fusion proteins: new developments and future perspectives. EMBO Mol. Med. 4, 1015–1028 (2012).
Levin, D., Golding, B., Strome, S. E. & Sauna, Z. E. Fc fusion as a platform technology: potential for modulating immunogenicity. Trends Biotechnol. 33, 27–34 (2015).
Dürr, U. H., Sudheendra, U. S. & Ramamoorthy, A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim. Biophys. Acta 1758, 1408–1425 (2006).
Sørensen, O. E. et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97, 3951–3959 (2001).
Park, M. D., Silvin, A., Ginhoux, F. & Merad, M. Macrophages in health and disease. Cell 185, 4259–4279 (2022).
Rosales, C. & Uribe-Querol, E. Phagocytosis: a fundamental process in immunity. BioMed. Res. Int. 2017, 9042851 (2017).
Nimmerjahn, F. & Ravetch, J. V. Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34–47 (2008).
Uribe-Querol, E. & Rosales, C. Phagocytosis: our current understanding of a universal biological process. Front. Immunol. 11, 1066 (2020).
Herrero-Cervera, A., Soehnlein, O. & Kenne, E. Neutrophils in chronic inflammatory diseases. Cell. Mol. Immunol. 19, 177–191 (2022).
Mittal, M., Siddiqui, M. R., Tran, K., Reddy, S. P. & Malik, A. B. Reactive oxygen species in inflammation and tissue injury. Antioxid. Redox Signal. 20, 1126–1167 (2014).
Saxton, R. A., Glassman, C. R. & Garcia, K. C. Emerging principles of cytokine pharmacology and therapeutics. Nat. Rev. Drug Discov. 22, 21–37 (2023).
Huang, X., He, D., Pan, Z., Luo, G. & Deng, J. Reactive-oxygen-species-scavenging nanomaterials for resolving inflammation. Mater. Today Bio 11, 100124 (2021).
Wang, S. et al. Accelerating diabetic wound healing by ROS-scavenging lipid nanoparticle–mRNA formulation. Proc. Natl Acad. Sci. USA 121, e2322935121 (2024).
Zhang, F. et al. Nanoparticle-modified microrobots for in vivo antibiotic delivery to treat acute bacterial pneumonia. Nat. Mater. 21, 1324–1332 (2022).
Maciá, M. D. et al. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50, 975–983 (2006).
Lee, A. S. et al. Methicillin-resistant Staphylococcus aureus. Nat. Rev. Dis. Prim. 4, 18033 (2018).
Zeng, C. et al. Leveraging mRNA sequences and nanoparticles to deliver SARS-CoV-2 antigens in vivo. Adv. Mater. 32, 2004452 (2020).
Chen, R. et al. Engineering circular RNA for enhanced protein production. Nat. Biotechnol. 41, 262–272 (2023).
Wang, C. et al. Blood–brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system. Nat. Mater. 24, 1653–1663 (2025).
Kim, M. et al. Dual SORT LNPs for multi-organ base editing. Nat. Biotechnol. https://doi.org/10.1038/s41587-025-02675-z (2025).
Devkota, S. P., Onah, C., Joshi, P. R., Adhikari, S. & Baral, P. Optimized method for higher yield of alveolar macrophage isolation for ex vivo studies. Heliyon 10, e37221 (2024).
Xue, Y. et al. LNP–RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment. Nat. Commun. 16, 2198 (2025).
Chen, S. et al. Nanotechnology-based mRNA vaccines. Nat. Rev. Methods Prim. 3, 63 (2023).
Mukherjee, A. et al. Engineered mutant α-ENaC subunit mRNA delivered by lipid nanoparticles reduces amiloride currents in cystic fibrosis-based cell and mice models. Sci. Adv. 6, eabc5911 (2020).
Witten, J. et al. Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy. Nat. Biotechnol. https://doi.org/10.1038/s41587-024-02490-y (2024).
Kim, J. et al. Engineering lipid nanoparticles for enhanced intracellular delivery of mrna through inhalation. ACS Nano 16, 14792–14806 (2022).
Sun, Y. et al. In vivo editing of lung stem cells for durable gene correction in mice. Science 384, 1196–1202 (2024).
Facchini, M., De Fino, I., Riva, C. & Bragonzi, A. Long term chronic Pseudomonas aeruginosa airway infection in mice. J. Vis. Exp. 85, 51019 (2014).
van den Berg, E. et al. Role of the Fas/FasL system in a model of RSV infection in mechanically ventilated mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 301, L451–L460 (2011).
